Supernus Pharmaceuticals, Inc. (SUPN)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $1.52B
Last updated: Nov 17, 2026 at 11:06 AM ET
Supernus Pharmaceuticals, Inc. (SUPN) Earnings: Report Dates and Results
Supernus Pharmaceuticals (SUPN) is expected to report earnings on Feb 22, 2027. In the quarter ended Sep 30, 2026, Supernus Pharmaceuticals reported EPS of $0.78, above the $0.34 estimate. It beat the EPS estimate in 6 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
SUPN has an expected report date of Feb 22, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 36.4% above the $0.88 reported for the quarter ended Dec 31, 2025.
SUPN Earnings Call
The latest SUPN earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, SUPN beat 29 and missed 11. The widest gap in the table came in the quarter ended Sep 30, 2023, when EPS landed 200.00% above the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.78 | $0.34 | N/A | +129.41% | Beat | +27.9% | 2 | 0 up, 2 down | Oct 29, 2026 | N/A |
| Jun 30, 2026 | $0.39 | $0.30 | N/A | +30.00% | Beat | -57.1% | 3 | 1 up, 0 down | Aug 3, 2026 | $219.06M |
| Mar 31, 2026 | $0.21 | $0.28 | $0.27 - $0.28 | -25.00% | Miss | -52.3% | 2 | 1 up, 0 down | May 5, 2026 | $207.71M |
| Dec 31, 2025 | $0.88 | $0.41 | N/A | +115.15% | Beat | +60.9% | 2 | 1 up, 1 down | Feb 24, 2026 | $211.57M |
| Sep 30, 2025 | $0.61 | $0.82 | $0.33 - $1.52 | -25.61% | Miss | -44.5% | 3 | 2 up, 0 down | Nov 4, 2025 | $192.10M |
| Jun 30, 2025 | $0.91 | $0.47 | $0.41 - $0.52 | +93.62% | Beat | +35.8% | 2 | 0 up, 0 down | Aug 5, 2025 | $165.45M |
| Mar 31, 2025 | $0.44 | $0.37 | $0.29 - $0.46 | +18.92% | Beat | +83.3% | 3 | 1 up, 2 down | May 6, 2025 | $149.82M |
| Dec 31, 2024 | $0.55 | $0.52 | $0.45 - $0.56 | +5.44% | Beat | -38.4% | 3 | 1 up, 0 down | Feb 25, 2025 | $174.16M |
| Sep 30, 2024 | $1.10 | $0.44 | $0.35 - $0.55 | +150.00% | Beat | +358.3% | 3 | 0 up, 0 down | Nov 4, 2024 | $175.69M |
| Jun 30, 2024 | $0.67 | $0.39 | $0.32 - $0.44 | +71.79% | Beat | +36.7% | 3 | 0 up, 0 down | Aug 6, 2024 | $168.32M |
| Mar 31, 2024 | $0.24 | $0.38 | $0.29 - $0.48 | -36.84% | Miss | -64.7% | 3 | 0 up, 0 down | May 8, 2024 | $143.64M |
| Dec 31, 2023 | $0.89 | $0.55 | $0.38 - $0.84 | +61.82% | Beat | +107.0% | 3 | 0 up, 0 down | Feb 27, 2024 | $164.31M |
| Sep 30, 2023 | $0.24 | $0.08 | $0.02 - $0.32 | +200.00% | Beat | -53.8% | 3 | 0 up, 1 down | Nov 8, 2023 | $153.88M |
| Jun 30, 2023 | $0.49 | $0.21 | N/A | +133.33% | Beat | +250.0% | 1 | 0 up, 0 down | Aug 8, 2023 | $135.56M |
| Mar 31, 2023 | $0.68 | $0.31 | N/A | +119.35% | Beat | +58.1% | 3 | 0 up, 1 down | May 9, 2023 | $153.76M |
| Dec 31, 2022 | $0.43 | $0.68 | $0.49 - $0.87 | -36.76% | Miss | +975.0% | 3 | 0 up, 0 down | Feb 28, 2023 | $167.33M |
| Sep 30, 2022 | $0.52 | $0.46 | $0.16 - $0.47 | +13.04% | Beat | +30.0% | 3 | 0 up, 0 down | Nov 8, 2022 | $177.35M |
| Jun 30, 2022 | $0.14 | $0.29 | N/A | -51.72% | Miss | -67.4% | N/A | 0 up, 0 down | Aug 4, 2022 | $170.05M |
| Mar 31, 2022 | $0.43 | $0.45 | N/A | -4.44% | Miss | +290.9% | 3 | 0 up, 0 down | May 9, 2022 | $152.51M |
| Dec 31, 2021 | $0.04 | $0.05 | N/A | -16.67% | Miss | -93.0% | 3 | 0 up, 0 down | Feb 28, 2022 | $159.05M |
| Sep 30, 2021 | $0.40 | $0.23 | $0.18 - $0.30 | +73.91% | Beat | -45.9% | 4 | N/A | Nov 3, 2021 | $148.46M |
| Jun 30, 2021 | $0.43 | $0.20 | $0.11 - $0.27 | +115.00% | Beat | -33.8% | 4 | N/A | Aug 4, 2021 | $141.33M |
| Mar 31, 2021 | $0.11 | $0.24 | $0.18 - $0.31 | -54.17% | Miss | -72.5% | 4 | N/A | May 5, 2021 | $130.93M |
| Dec 31, 2020 | $0.57 | $0.52 | $0.36 - $0.73 | +9.62% | Beat | -8.1% | 4 | N/A | Feb 25, 2021 | $143.56M |
| Sep 30, 2020 | $0.74 | $0.27 | $0.20 - $0.37 | +174.07% | Beat | +37.0% | 4 | N/A | Nov 3, 2020 | $155.13M |
| Jun 30, 2020 | $0.65 | $0.42 | $0.24 - $0.48 | +54.76% | Beat | +6.6% | 4 | N/A | Aug 18, 2020 | $126.73M |
| Mar 31, 2020 | $0.40 | $0.28 | $0.16 - $0.39 | +42.86% | Beat | +17.6% | 5 | N/A | May 5, 2020 | $94.98M |
| Dec 31, 2019 | $0.62 | $0.59 | $0.56 - $0.73 | +5.08% | Beat | +29.2% | 6 | N/A | Feb 25, 2020 | $102.82M |
| Sep 30, 2019 | $0.54 | $0.59 | $0.53 - $0.64 | -8.47% | Miss | +3.8% | 6 | N/A | Nov 5, 2019 | $102.14M |
| Jun 30, 2019 | $0.61 | $0.60 | $0.51 - $0.66 | +1.67% | Beat | +7.0% | 8 | N/A | Aug 6, 2019 | $104.69M |
| Mar 31, 2019 | $0.34 | $0.47 | $0.31 - $0.59 | -27.66% | Miss | -30.6% | 8 | N/A | May 7, 2019 | $83.10M |
| Dec 31, 2018 | $0.48 | $0.29 | $0.21 - $0.34 | +65.52% | Beat | +9.1% | 9 | N/A | Feb 26, 2019 | $121.72M |
| Sep 30, 2018 | $0.52 | $0.42 | $0.24 - $0.49 | +23.81% | Beat | +73.3% | 10 | N/A | Nov 6, 2018 | $100.23M |
| Jun 30, 2018 | $0.57 | $0.45 | $0.37 - $0.50 | +26.67% | Beat | +72.7% | 9 | N/A | Aug 7, 2018 | $97.83M |
| Mar 31, 2018 | $0.49 | $0.32 | $0.20 - $0.45 | +53.13% | Beat | +157.9% | 8 | N/A | May 8, 2018 | $89.12M |
| Dec 31, 2017 | $0.44 | $0.27 | $0.19 - $0.33 | +62.96% | Beat | +18.9% | 8 | N/A | Feb 27, 2018 | $88.44M |
| Sep 30, 2017 | $0.30 | $0.28 | $0.24 - $0.29 | +7.14% | Beat | -18.9% | 8 | N/A | Nov 6, 2017 | $80.40M |
| Jun 30, 2017 | $0.33 | $0.24 | $0.23 - $0.25 | +37.50% | Beat | +83.3% | 7 | N/A | Aug 2, 2017 | $75.83M |
| Mar 31, 2017 | $0.19 | $0.25 | N/A | -24.00% | Miss | +90.0% | N/A | N/A | May 9, 2017 | $57.58M |
| Dec 31, 2016 | $0.37 | $0.34 | N/A | +8.82% | Beat | +164.3% | N/A | N/A | Jan 20, 2017 | $272.45M |
Estimates made before a stock split are shown on the same share basis as the reported EPS.
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $2.84, up 11.1% from the year before. It was $1.02 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $2.84 | +11.1% |
| Dec 31, 2024 | $2.56 | +11.2% |
| Dec 31, 2023 | $2.30 | +51.3% |
| Dec 31, 2022 | $1.52 | +55.1% |
| Dec 31, 2021 | $0.98 | -58.5% |
| Dec 31, 2020 | $2.36 | +11.8% |
| Dec 31, 2019 | $2.11 | +2.4% |
| Dec 31, 2018 | $2.06 | +63.5% |
| Dec 31, 2017 | $1.26 | +23.5% |
| Dec 31, 2016 | $1.02 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,200 words across 8 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 4,151 | 8 | |
| 2026Q1 | Mar 31, 2026 | 4,134 | 10 | |
| 2025Q4 | Dec 31, 2025 | 5,571 | 10 | |
| 2025Q3 | Sep 30, 2025 | 4,934 | 9 | |
| 2025Q2 | Jun 30, 2025 | 4,905 | 9 | |
| 2025Q1 | Mar 31, 2025 | 3,984 | 7 | |
| 2024Q4 | Dec 31, 2024 | 4,621 | 9 | |
| 2024Q3 | Sep 30, 2024 | 4,983 | 7 |
2026Q3 Earnings Call
Opening remarks
Peter Vozzo Investor Relations Representative Thank you, Angela. Good afternoon, everyone, and thank you for joining us today for Supernus Pharmaceuticals' Third Quarter 2026 Financial Results Conference Call. Today, after the close of the market, the company issued a press release announcing these results. On the call with me today are Supernus' Chief Executive Officer, Jack Khattar, and Chief Financial Officer, Tim Dec. Today's call is being made available via the Investor Relations section of the company's website at www.ir.supernus.com. Before we begin, I'd like to remind you that we will be making forward-looking statements. All of these statements are based on the beliefs and expectations of management as of today. Actual events or results could differ materially. We refer you to the documents we and Indivior Pharmaceuticals have filed with the SEC, including periodic reports under the heading Risk Factors, which identify important factors that could cause actual results to differ materially from those expressed by the company verbally, as well as statements made within this afternoon's press release. This call is being webcast live, and a link can be found at the Supernus website at ir.supernus.com. A replay will be made available shortly after this call is concluded. I'll now turn the call over to Jack.
Jack Khattar CEO Thank you, Peter. Good afternoon, everyone, and thanks for taking the time to join us on today's call. Today, we will focus on Supernus's strong 2026 third-quarter and year-to-date results, which show the continued momentum across our commercial portfolio, specifically our growth products. After walking through these results, I'll provide a brief update on our transformative merger with Indivior Pharmaceuticals. For the third quarter of 2026, combined revenues of our growth products, Qelbree, ZURZUVAE, ONAPGO, and GOCOVRI, increased by 43% compared to the same period last year. Starting with Qelbree in the third quarter, prescriptions as reported by IQVIA grew by 18% over the third quarter of 2025, outpacing the 10% growth in the ADHD market. Net sales were $91 million in the third quarter, representing a 12% increase over last year. Similarly, for the nine months ended September 30, 2026, Qelbree achieved robust growth of 18% in prescriptions and 15% in net sales compared to the same period last year. Net sales for the nine-month period reached an all-time high of $258 million. Qelbree's growth over the last year continues to come from both patient populations, with third-quarter adult prescription growth of 25% and pediatric prescription growth of 16%. In addition, the total quarterly number of prescribers for Qelbree reached a high of approximately 46,000. Moving on to ONAPGO. During the third quarter of 2026, ONAPGO generated net sales of $17.1 million, up 27% compared to the second quarter of 2026.
Frequently Asked Questions About SUPN
When is Supernus Pharmaceuticals's next earnings date?
Supernus Pharmaceuticals's next earnings report is expected for Feb 22, 2027.
Did SUPN beat earnings estimates last quarter?
Yes. Supernus Pharmaceuticals reported EPS of $0.78 for the quarter ended Sep 30, 2026, above the $0.34 estimate, a 129.41% surprise.
What EPS do analysts expect from SUPN next quarter?
The consensus EPS estimate for Supernus Pharmaceuticals for the quarter ending Dec 31, 2026 is $1.20 from 6 analysts, with estimates from $1.07 to $1.28.
How often does SUPN beat earnings estimates?
Supernus Pharmaceuticals beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +42.74%.
SUPN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors